Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintains a price target of $85.
August 09, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Apellis Pharmaceuticals and maintains a price target of $85.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100